Welcome to our dedicated page for Repligen SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Repligen Corporation's SEC filings document financial reporting, governance and public-company capital structure for a Nasdaq-listed life sciences company in bioprocessing technology. Recent Form 8-K reports attach earnings releases for quarterly and annual results, financial guidance and non-GAAP measures such as organic revenue, adjusted operating income, adjusted EPS and adjusted EBITDA.
The filing record also includes definitive proxy materials covering board matters, executive compensation and equity awards, along with Form 8-K disclosures on officer appointments, principal accounting officer responsibilities, financial reporting oversight and Sarbanes-Oxley-related infrastructure. Securities registration disclosures identify RGEN common stock, par value $0.01 per share, on the Nasdaq Global Select Market.
Repligen Corporation has appointed Violetta Hughes as Chief Accounting Officer, effective September 1, 2025, making her the company’s principal accounting officer. Chief Financial Officer Jason K. Garland will remain in his role, with more of his time directed toward corporate strategy, financial planning and analysis, capital markets and growth initiatives.
Hughes brings over 25 years of finance and accounting experience from prior chief accounting officer and controllership roles at Azenta, Akebia Therapeutics and AMAG Pharmaceuticals, with a background in financial governance and Sarbanes–Oxley compliance. Her compensation package includes a $395,000 annual base salary, a $150,000 signing bonus, an annual target bonus of up to 50% of base salary, and annual equity awards totaling $750,000 in restricted stock units and stock options that vest in equal installments over five years.
Repligen Corp director Martin D. Madaus, through the Martin D. Madaus 2011 Revocable Trust, bought 1,800 shares of Repligen common stock in an open-market purchase. The weighted average price was $112.128 per share, with trades ranging from $111.72 to $112.35. Following these transactions, Madaus directly holds 5,586 shares, the revocable trust holds 1,800 shares, and a spouse trust holds 11 shares.